Clinical Trial Update: Polyspecific Antibodies in Lymphoproliferative T-cell Disorders [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial of polyspecific antibodies for peripheral T-cell lymphoma is currently recruiting, sponsored by Xenothera SAS.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Polyspecific antibodies

Snippet

Sponsor: Xenothera SAS | Conditions: Peripheral T Cells Lymphoma (PTCL) | Phase 1, Phase 2 | Status: RECRUITING